A5033085910- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Bladder and Urothelial Cancer Treatments
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Prostate Cancer Treatment and Research
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Urinary and Genital Oncology Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Biosimilars and Bioanalytical Methods
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Medical Imaging Techniques and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
Pfizer (United States)
2024-2025
Seagen (United States)
2020-2024
City of Hope
2023-2024
Fred Hutch Cancer Center
2015-2021
University of Washington
2012-2021
Seattle Cancer Care Alliance
2017-2019
University of Washington Medical Center
2016-2019
Seattle University
2017-2018
Yale University
2010-2011
In the primary analysis of HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) progression-free (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy safety outcomes, including final OS outcomes from follow-up HER2CLIMB.HER2CLIMB is a randomized, double-blind, placebo-controlled trial locally advanced or HER2+ cancer, brain metastases. Patients were randomized : 1...
It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which associated poor prognosis. Previous reports the HER2CLIMB trial have demonstrated tucatinib in combination trastuzumab and capecitabine provides survival intracranial benefits for ERBB2-positive MBC BMs.
To evaluate the efficacy and safety of tucatinib trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC).
Abstract Efficient conservation planning requires knowledge about targets, threats to those costs of and the marginal return additional efforts. Systematic typically only takes a small piece this complex puzzle into account. Here, we use return‐on‐investment ( ROI ) approach prioritise lands for at county level in conterminous USA. Our accounts species richness, area, proportion species' ranges already protected, threat land conversion costs. Areas selected by complementarity‐based greedy...
Background Delays from the diagnosis of muscle‐invasive bladder cancer (MIBC) to radical cystectomy (RC) longer than 12 weeks result in higher mortality and shorter progression‐free survival. This study sought identify factors associated with RC delays determine whether care current treatment paradigm, which includes neoadjuvant chemotherapy (NAC), affect Methods Subjects American Joint Committee on Cancer stage II urothelial carcinoma who underwent 2004 2012 were identified linked...
4007 Background: Biliary tract cancer (BTC) is an aggressive malignancy with a poor prognosis, and current treatment options for advanced BTC are limited, second-line therapy, FOLFOX S-1 offering objective response rate (ORR) of 5.0% 7.5%, respectively. Up to 20% BTCs overexpress human epidermal growth factor receptor 2 (HER2). Tucatinib (TUC) highly selective HER2-directed TKI approved HER2-positive (HER2+) metastatic breast colorectal cancer. Discussed here the efficacy safety results TUC...
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell and differentiation, is overexpressed in several tumor types, including breast, gastric colorectal cancer. HER2-targeted therapies have shown clinical activity against these resulting regulatory approvals. However, the efficacy of HER2 tumors with mutations has not been widely investigated. SGNTUC-019 an open-label, phase basket study evaluating tucatinib, a tyrosine kinase inhibitor, combination...
BACKGROUND We sought to identify potential clinical variables associated with outcomes after radium‐223 therapy in routine practice. METHODS Consecutive non‐trial mCRPC patients who received ≥1 dose of radium dichloride‐223 at four academic and one community urology‐specific cancer centers from May 2013 June 2014 were retrospectively identified. Association baseline on‐therapy number doses including overall survival analyzed using chi‐square statistics, cox proportional hazards, Kaplan–Meier...
1043 Background: Tucatinib (TUC) is an oral tyrosine kinase inhibitor (TKI) highly specific for HER2. TUC approved use in combination with trastuzumab (T) and capecitabine (C) patients (pts) without brain metastases (BM) who have received 1 or more prior anti-HER2–based regimens the metastatic setting. In primary analysis from pivotal HER2CLIMB trial, addition of to T C pts HER2+ breast cancer showed a statistically significant clinically meaningful prolongation progression-free (PFS) (HR =...
1105 Background: Approximately 2-5% of breast cancers harbor HER2 mutations, often occurring in hormone receptor-positive (HR+) disease. There are currently no approved treatment options for patients (pts) with HER2-mutated metastatic cancer (HER2-mut MBC). Tucatinib (TUC) is a tyrosine kinase inhibitor highly selective and previously treated HER2+ MBC or without brain metastases combination trastuzumab (Tras) capecitabine. Here, we report the efficacy safety results TUC combined Tras pts...
TPS1097 Background: Tucatinib (TUC) is an oral, reversible, small molecule tyrosine kinase inhibitor highly selective for human epidermal growth factor receptor 2 (HER2) with minimal inhibition of (EGFR). In the pivotal, randomized HER2CLIMB trial (NCT02614794), combination TUC + trastuzumab (T) capecitabine (C) demonstrated statistically significant and clinically meaningful improvements in progression free survival (PFS), overall (OS), PFS patients (pts) brain metastases (BM), compared to...
Background: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented the model. We sought evaluate whether predicts VTE retrospective multinational data set of metastatic UC/VH. Methods: Patients diagnosed UC/VH who received chemotherapy eligible. Those incomplete or miscoded excluded. scores calculated based on pretreatment categorized...
Abstract Venous thromboembolism ( VTE ) is common in cancer patients. However, little known about risk metastatic urothelial carcinoma or variant histologies UC / VH ). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of on survival Patients diagnosed with from 2000 2013 were included this multicenter retrospective, international study 29 academic institutions. Cumulative 6‐month incidence rates...
Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may additional later-line after progression. Our study compares outcomes subsequent (sPBC) versus non-platinum-based (sNPBC).
Patients diagnosed with metastatic colorectal cancer (mCRC) have a poor prognosis survival ranging 2-3 years. The prevalence of human epidermal growth factor receptor 2 (HER2) amplification is approximately 3-4% in mCRC and increases up to 8% patients KRAS/NRAS/BRAF wild-type (WT) CRC tumors. Tucatinib highly selective HER2-directed tyrosine kinase inhibitor that, combination trastuzumab, has demonstrated clinically meaningful activity chemotherapy-refractory, HER2-positive (HER2+), RAS WT...
In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. We evaluated the impact of on health-related quality life (HR-QoL) HER2CLIMB.Patients were randomised 2:1 to or placebo combined trastuzumab capecitabine. Starting protocol version 7, EuroQol 5 Dimensions Levels (EQ-5D-5L) questionnaire EQ visual analogue scale (VAS) administered at day 1 cycle 1, every two...